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ABBREVIATIONS LIST
IGF1= insulin-like growth factor 1
PI3K=Phosphatidylinositol-4,5-bisphosphate 3-kinase
AKT= Protein Kinase B
ERK1/2= extracellular signal–regulated kinases 1/2
AMPK= AMP-activated protein kinase
mTOR= mammalian Target of Rapamycin
MAPK= mitogen-activated protein kinase
NFAT= nuclear factor of activated T cells
GRK= GPCR receptor kinases
PDE5= phosphodiesterase 5
PKCα= Protein kinase C alpha
CaMKII= Ca2+/calmodulin-dependent kinase II 
Myh6= myosin, heavy polypeptide 6, cardiac muscle, alpha
Rcan1.4= regulator of calcineurin 1.4
Ptgs-2= prostaglandin-endoperoxide synthase 2
Cox-2= cyclooxygenase 2 
Col3a1= collagen, type III, alpha 1
Col1a1= collagen, type I, alpha 1
p38 MAPK= mitogen-activated protein kinase p38 
Jnk= c-jun N-terminal kinase
Tgfβ= transforming growth factor beta
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ABSTRACT
Previous studies have demonstrated that activation of calcineurin induces pathological cardiac hypertrophy. In 
these studies, loss-of-function was mostly achieved by systemic administration of the calcineurin inhibitor 
cyclosporin A. The lack of conditional knockout models for calcineurin function has impeded progress toward 
defining the role of this protein during the onset and the development of cardiac hypertrophy in adults. Here, we 
exploited a mouse model of cardiac hypertrophy based on the infusion of a hypertensive dose of angiotensin II 
(AngII) to model the role of calcineurin in cardiac hypertrophy in adulthood. AngII-induced cardiac 
hypertrophy in adult mice was reduced by treatment with cyclosporin A, without affecting the associated 
increase in blood pressure, and also by induction of calcineurin deletion in adult mouse cardiomyocytes, 
indicating that cardiomyocyte calcineurin is required for AngII-induced cardiac hypertrophy. Surprisingly, 
cardiac-specific delection of calcineurin, but not treatment of mice with cyclosporin A, significantly reduced 
AngII-induced cardiac fibrosis and apoptosis. Analysis of pro-fibrotic genes revealed that AngII-induced 
expression of Tgfβ-family members and Lox was not inhibited by cyclosporin A but was markedly reduced by 
cardiac-specific calcineurin deletion. These results show that AngII induces a direct, calcineurin-dependent pro-
hypertrophic effect in cardiomyocytes, as well as a systemic hypertensive effect that is independent of 
calcineurin activity.
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1. INTRODUCTION
Cardiac hypertrophy (CH) is the main mechanism by which the heart reduces stress on the ventricular walls [1-
3]. In the initial response to cardiac overload, heart function is maintained through increased protein synthesis 
and cardiomyocyte enlargement, accompanied by sarcomere reorganization. This cardiac response can be 
induced in physiological or pathological situations. During pregnancy or intensive exercise training, CH is an 
advantageous adaptation; however, in response to hypertension, aortic stenosis, or myocardial infarction, the 
initial compensatory response to cardiac stress becomes maladaptive and constitutes a major risk for the 
development of heart failure [4].
The precise mechanisms underlying physiological and pathological CH are not fully understood; however, 
pathological cardiac remodeling is characterized by the development of fibrosis that contributes to loss of heart 
function. Several studies indicate that physiological and pathological cardiac remodeling involve different 
biochemical stimuli and intracellular signaling pathways, which could explain their differing outcomes [1-3]. 
Physiological cardiac hypertrophy is triggered by a limited number of growth factors (thyroid hormone, insulin, 
insulin-like growth factor 1 and vascular endothelial growth factor) and mechanical stimuli that activate the 
IGF1/PI3K/AKT, ERK1/2, AMPK, and mTOR-dependent signaling pathways. In contrast, pathological 
hypertrophy is activated by a plethora of neuro-hormonal factors and biomechanical stimuli and intracellular 
pathways, including MAPK kinases, GRK, PDE5, PKCα, CAMKII, and Ca2+-dependent effectors. Prominent 
inducers of pathological CH include the calcium-calmodulin-dependent phosphatase calcineurin (Cn) and its 
substrate NFAT [5]. Although numerous gain-of-function studies have demonstrated that Cn and NFAT both 
induce a pathological phenotype involving cardiac growth [5, 6], most loss-of-function experiments have been 
performed with the pharmacological Cn inhibitors cyclosporin A (CsA) and FK506 (tacrolimus) or mice 
constitutively lacking Cn or NFAT [5]. To date, 2 studies have described the generation of mice with cardiac-
specific loss of Cn in the heart, by deletion of the Cnb1 gene [7, 8]. However, the use of a non-inducible 
cardiomyocyte driver in these mice causes cardiac Cn deletion in the perinatal period, when cardiomyocytes are 
proliferating [9], resulting in depressed cardiac function and 50% lethality at 4-6 months [7, 8]. To our 
knowledge, no mouse model to date has modeled the role of cardiac Cn during CH in adulthood, when the 
disease develops. 
Hypertension is a major inducer of pathological cardiac remodeling characterized by left ventricular 
hypertrophy and cardiac fibrosis [4, 10]. High blood pressure, such as that induced by angiotensin II (AngII), is 
a well-known mediator of CH [11]. Recent evidence suggests that AngII also exerts a pressor-independent and 
direct action on cardiac remodelling [12-14]. Previous studies in animal models of hypertension demonstrated 
the participation of Cn in CH [15-17]; however, the precise role of Cn in CH onset and progression has not been 
defined. For the present study, we generated a mouse model of inducible and cardiac-specific Cn deletion. 
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Through a combination of genetic experimental and pharmacological approaches, we show that Cn plays an 
essential role in the development of AngII-mediated CH, whereas cardiac fibrosis is mediated by CsA-
insensitive mechanisms involving members of the Tgfβ and Lox families.
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2. RESULTS
2.1. A Cn-inhibitory CsA concentration reduces AngII-induced cardiac hypertrophy in mice without 
affecting hypertension.
CsA at higher doses than those used therapeutically to achieve Cn inhibition and immunosuppression [18, 19] 
reduces CH induced by non-pressor doses of AngII in rats [20]. We therefore tested whether lower (clinical) 
doses of CsA would prevent CH induced by pro-hypertensive AngII concentrations. We treated wild-type mice 
for 21 days with AngII (60 µg/kg/h) and a pharmacological CsA dose (0.208 mg/kg/h). This CsA dose is 10-
fold below that used in rats [20]. AngII induced an increase in systolic blood pressure (Table 1) that was 
unaffected by co-treatment with CsA (Table 1). Postmortem analysis revealed a significant AngII-induced 
increase in ventricular mass that was inhibited by CsA (Fig. 1A). 
To determine whether the AngII-induced increase in cardiac mass was due to increased cardiomyocyte size, we 
measured cardiomyocyte cell area in cardiac cross-sections. Cardiomyocyte area was significantly enlarged in 
AngII-infused mice, and this increase was again attenuated by CsA (Fig. 1B). Consistent with these 
morphological data, echocardiography in live AngII-infused mice revealed notable increases in left ventricular 
posterior wall (LVPW) and interventricular septum (IVS) thickness (Table 1). CsA did not modify ventricular 
wall thickness in sham-implanted animals, but attenuated the increase in wall thickness induced by AngII 
infusion (Table 1). Analysis of ejection fraction (EF) revealed that AngII and CsA treatment had no significant 
impact on systolic cardiac function (Table 1). 
These results suggest that Cn activation plays an important role in AngII-induced CH and indicate that 
pharmacological Cn inhibition with CsA significantly reduces cardiac enlargement without reverting AngII-
induced hypertension.
2.2. AngII triggers early activation of Cn-dependent gene expression and the cardiac hypertrophy 
program
We next investigated whether AngII activates Cn-dependent gene expression in the heart. Cardiac mRNA 
expression of the Cn target genes Rcan1.4 and Ptgs-2 [21, 22] was elevated in wild-type mice after AngII 
treatment for 15 h, decreasing to basal levels after 3 days (Fig. 2A). This transcriptional effect was reflected in 
the induction of cardiac Rcan1.4 and Cox-2 protein expression as soon as 1 day after treatment (Fig. 2B and 
2C). Rcan1.4 expression returned to baseline levels after 2 days of AngII infusion, whereas maximum Cox2 
expression was maintained at this time (Fig. 2C). Treatment with either a low CsA dose (0.208 mg/kg/h) or a 
high CsA dose (0.832 mg/kg/h) markedly reduced AngII-induced cardiac Rcan1.4 and Cox2 expression (Fig. 
2B and 2C), suggesting that Cn activation was required for their upregulation. 
Given that AngII induced a very early activation of cardiac Cn-dependent gene expression, we analyzed 
whether AngII treatment also results in an early development of the hypertrophic phenotype. CH development 
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was monitored in wild-type mice treated with AngII for 1 or 3 days. Notably, as early as 3 days after the 
initiation of AngII infusion, mice showed significant increases in ventricular mass (Fig. 2D), cardiomyocyte 
area (Fig. 2E), and IVS thickness (Fig. 2F). This early AngII-induced CH was attenuated by treatment with 
CsA (Fig. 2D-F).
These results show that AngII induces an early expression of Cn-dependent genes in the heart that is 
concomitant with the early appearance of a CH phenotype. The blockade of these effects with Cn inhibitors 
suggests that activation of Cn signaling mediates AngII-induced CH.
2.3. AngII-induced CH requires cardiomyocyte Cn.
Although our experiments were performed with low CsA concentration, this immunosuppressant can have 
effects unrelated to Cn and might interfere with targets others than Cn [23]. Knockout models in principle 
represent a more precise alternative to the use of pharmacological Cn inhibitors. However, none of the reported 
mouse models allows study of the role of Cn in the development of CH, a condition of adulthood: mice 
systemically lacking Cnb1 die during embryogenesis [24], and Cn deletion using the alpha-myosin heavy chain 
(Myh6) promoter results in death in early-mid adulthood [7, 8]. To address this issue, we generated a mouse 
model allowing induced cardiomyocyte-specific deletion of floxed Cnb1. In these mice Cnb1 deletion is 
induced in cardiomyocytes expressing Cre recombinase under the control of the Myh6 promoter in a tamoxifen-
inducible manner. Cnb1∆/flox mice [25] were crossed with Myh6CreERT2 mice [26] to obtain Cnb1Δ/flox; 
Myh6CreERT2 mice or Cnb1flox/flox; Myh6CreERT2 mice, hereafter called Cnb1-floxMyh6 mice (details in Methods).
Treatment of Cnb1-floxMyh6 mice with 4-hydroxy tamoxifen (Tx) strongly reduced cardiac Cnb1 mRNA and 
protein expression (Fig. S1A and Fig. 3A). Western blot analysis revealed unaltered CnB protein expression in 
thymus, aorta, liver, and kidney of Tx-treated Cnb1-floxMyh6 mice (Fig. 3B), confirming specific deletion in 
cardiac tissue. The destabilization of the catalytic subunit CnA in the absence of the regulatory subunit CnB has 
been previously demonstrated in in vivo models [7, 27]. Similarly, we confirmed that the deletion of cardiac 
Cnb1 expression resulted in similar reduction of the protein levels of both CnB and CnA (Fig. 3A and Fig. 
S1B). 
Having confirmed the specificity and efficacy of Cn deletion in Tx-treated Cnb1-floxMyh6 mice, we infused 
them with AngII for 1 day and determined the cardiac mRNA expression of the Cn target genes Rcan1.4 and 
Ptgs2, as an index of Cn pathway activity. Rcan1.4 and Ptgs2 mRNA levels were markedly lower in Tx-treated 
mice than in untreated controls (Fig. 3C), and similar results were obtained for Rcan1.4 protein (Fig. 3D), 
suggesting that inducible, cardiac-specific Cn ablation inhibits the expression of Cn-dependent genes in the 
hearts of AngII-treated mice.
We next analyzed the effect of cardiac Cnb1 deletion in adult mice on AngII-induced CH. Mice treated with Tx 
or vehicle were infused with AngII for 21 days. The induced loss of cardiac Cn diminished AngII-induced 
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increases in ventricular mass and cardiomyocyte cross-sectional area (Fig. 4A and 4B), and echocardiography 
confirmed attenuation of the AngII-induced increase in left ventricular wall thickness (Table 2). Induced 
cardiac Cnb1 deletion was equally effective as CsA-mediated inhibition of Cn phosphatase activity at 
preventing AngII-induced CH. 
These results implicate cardiomyocyte Cn in CH and validate Cnb1-floxMyh6 mice as a model for investigating 
the mechanisms underlying the onset and progression of hypertrophy in the adult heart.
2.4. Cardiac Cn mediates AngII-induced fibrosis and pro-fibrotic gene expression.
Cardiac fibrosis—the abnormal accumulation of extracellular matrix proteins (ECM) such as collagens and 
fibronectins in the myocardium—is a common feature of pathological CH [2]. In wild-type mice, AngII 
treatment for 21 days induced significant myocardial fibrosis that was not prevented by CsA (Fig. 5A). 
Histological analysis at earlier time points revealed marked cardiac fibrosis on day 3 of AngII stimulation; CsA 
not only did not prevent this but seemed to exacerbate it (Fig. 5B). The histological data correlated with the 
mRNA expression of Col3a1, which encodes one of the two fibrillar collagen types that form the myocardial 
extracellular matrix (Fig. 5C). These results suggest that AngII-induced cardiac fibrosis is Cn-independent; 
however, AngII-mediated cardiac fibrosis was strongly reduced by Cn deletion in the cardiomyocytes of Cnb1-
floxMyh6 mice (Fig. 5D). As in wild type mice, CsA did not prevent AngII-induced heart fibrosis in Cnb1-
floxMyh6 mice, demonstrating that the divergence between the results obtained with pharmacological and genetic 
Cn inhibition was not due to the use of different mouse strains (Fig. 5D). As observed in mice treated with 
AngII for 21 days, the cardiac Cnb1 deletion attenuated CH and fibrosis as early as 3 days after AngII infusion 
(Fig. 6).
Cardiomyocyte death has been described as a possible mechanism responsible for induction of the fibrotic 
response [28], and the presence of apoptotic cells in cardiac tissue has been widely reported in AngII-treated 
rodents [11, 29, 30]. TUNEL assays to evalute the extent of apoptosis in AngII-treated mice in the 
pharmacological and genetic models revealed a significant increase in the number of apoptotic cells after 3 days 
of AngII-treatment (Fig. 7A and 7B). Similar to the fibrotic response, AngII-induced heart apoptosis was 
unaffected by CsA and was prevented by Cn deletion in cardiomyocytes (Fig. 7A and 7B). Apoptosis and 
fibrosis thus show the same divergence in the response to pharmacological and genetic Cn inhibition. 
The elevated and abnormal deposition of collagens during cardiac fibrosis is regulated at the levels of synthesis, 
maturation, and degradation [31]. Cytokines and growth factors implicated in fibrosis induction include 
interleukin-6 (Il-6) and members of the Tgfβ family [32]. We therefore examined whether the expression of 
pro-fibrotic genes was differently affected by pharmacological and genetic Cn inhibition during AngII-induced 
cardiac fibrosis. Gene expression of Il-6, Tgfβ1, Tgfβ2, and the Tgfβ-induced gene Tgfβi was significantly 
upregulated in the hearts of wild type mice after 1 day of AngII infusion, whereas Tgfβ3 mRNA was 
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significantly increased after AngII infusion for 3 days (Fig. 8A). Analysis of gene expression in the hearts of 
Tx-treated Cnb1-floxMyh6 mice and CsA-treated wild-type mice revealed suppression of AngII-induced Il-6 
expression in both cases, whereas AngII-induced Tgfβ3 upregulation was unaffected (Fig. 8B). In contrast, 
AngII-induced Tgfβ1, Tgfβ2, and Tgfβi expression was not inhibited by CsA in wild-type mice but was reduced 
by cardiac-specific Cnb1 deletion (Fig. 8B). Tgfβ family members can trigger the activation and maturation of 
collagen expression [32], suggesting that the differential Tgfβ expression pattern might underlie the divergent 
fibrotic phenotypes observed. However, AngII-induced mRNA expression of Col1a1 and Col3a1 was not 
reduced in response to cardiac Cnb1 deletion, and CsA further potentiated their expression (Fig. 8C).
Processing of collagens into mature fibrils requires covalent cross-linking mediated by members of the lysyl 
oxidase family [33], the most prominent member is Lox. AngII-induced upregulation of Lox mRNA expression 
was not affected by CsA treatment in wild type mice, but was significantly decreased by deletion of 
cardiomyocyte Cn (Fig. 8D). This pattern was reflected at the protein level, with AngII-induced Lox protein 
expression not reduced by CsA, and even increased, whereas cardiac Cnb1 deletion blunted this upregulation 
(Fig. 8E). As reported for transaortic constriction-induced CH [34], AngII also upregulated the other Lox family 
members (Loxl1, Loxl2, Loxl3, and Loxl4) in the heart (Fig. 9). Cardiac Cnb1 deletion blocked AngII-induced 
upregulation of Loxl4, but not Loxl1, Loxl2, or Loxl3 (Fig. 9).
These results indicate that cardiomyocyte Cn regulates AngII-induced cardiac fibrosis and expression of 
essential pro-fibrotic genes in murine heart.
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3. DISCUSSION
In this study, we provide evidence demonstrating that AngII at hypertensive doses activates Cn signaling in the 
mouse heart concurrently with the development of cardiac hypertrophy. Remarkably, inhibition of Cn with low 
CsA doses impaired AngII-induced CH but did not reverse the associated blood pressure increase, suggesting 
that AngII exerts a direct Cn-dependent pro-hypertrophic effect on cardiac cells and an indirect Cn-independent 
hypertensive effect. These results are consistent with CsA-mediated reduction of AngII-linked CH in other 
mouse models, including renal damage-induced CH [16] and aldosterone-induced CH [17]. Our findings 
indicate that in a pathological setting AngII directly activates specific pro-hypertrophic pathways in cardiac 
cells that differ from those triggered by hypertension-derived hemodynamic stimuli. Supporting this idea, 
subpressor AngII doses induce CH in rats [20]. Furthermore, AngII-dependent activation of p38 MAPK 
signaling has been linked to a direct action on mouse cardiac cells, whereas activation of Erk and Jnk is linked 
to AngII-induced mechanical stress on the heart [35]. These results suggest that treatment of pathological 
cardiac hypertrophy in patients presenting high blood pressure would require blockade of specific intracellular 
pathways activated by hypertension-independent mechanisms.
Pharmacological inhibition of Cn with CsA is a useful tool for investigating the involvement of Cn in CH 
progression. However, systemic drug delivery does not target the specific contribution of cardiac Cn. Here, we 
explored the precise implication of cardiac Cn in the onset and progression of CH in adulthood, using a newly 
generated mouse model of inducible cardiomyocyte-specific Cnb1 deletion, based on floxed Cnb1 and Cre 
recombinase expression under the control of the inducible cardiac promoter Myh6. In this mouse model, 
deletion of CnA and CnB occurs in a similar manner, which implies that Cn-mediated phosphatase activity in 
the heart is inhibited upon conditional deletion of Cnb1, as this also led to the loss of the Cn catalytic subunit 
(CnA). These results therefore suggest that genetic and pharmacological approaches both result in the inhibition 
of Cn activity.
We have found that conditional deletion of cardiomyocyte Cnb1 prevents AngII-induced CH. These results are 
consistent with previous reports showing inhibition of AngII-mediated heart weight gain in mouse models with 
constitutive deficiency of the catalytic subunit CnAβ or the Cn substrates NFATc3 or NFATc2 [36-38]. 
However, it is important to note that these studies examined induction of CH by pressure-overload or Cn-
overexpression, which are not mediated by systemic hypertension, and AngII was used only to confirm that 
deletion of these Cn/NFAT signaling pathway components were involved in AngII-mediated heart weight 
increase. Here, we have characterized the cardiac hypertrophy induced by a well-characterized pro-hypertensive 
dose of AngII [39-42] and analyzed the role of cardiomyocyte Cn in cardiomyocyte size, ventricular wall 
thickness, fibrosis, expression of pro-fibrotic genes, and apoptosis. Our data indicate that cardiomyocyte Cn in 
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adulthood regulates cardiac remodeling and function during the onset and development of AngII-mediated 
cardiac hypertrophy.
Remarkably, cardiac-specific Cn deletion in healthy adult mice did not impair cardiac function (Tx-treated 
sham-implanted Cnb1-floxMyh6 mice, Table 2). A cardiac-specific Cn knockout mouse was recently generated 
[7, 8], but in this model, cardiac Cn deletion is not inducible and begins at the perinatal stage, resulting in 
impaired contractility and cardiac growth, and death between 4 and 6 months after birth [7, 8]. The differences 
between these results and ours suggest that Cn plays different roles in cardiac homeostasis during postnatal 
development and adulthood and are consistent with data showing that Cn signaling differs between neonatal and 
adult cardiomyocytes [43]. 
Although most animal models of CH are based on chronic stimulation, we show here that mice display Cn-
dependent CH markers as soon as 3 days after AngII infusion (Fig. 2 and Fig. 6). Our results show that AngII-
induced activation of cardiac Cn mediates CH progression from the onset of the disease. We also found that Cn 
inhibition by CsA infusion or cardiac-specific Cnb1 deletion prevents AngII-induced cardiomyocyte 
hypertrophy. However, these 2 approaches to Cn inhibition have divergent effects on AngII-induced cardiac 
fibrosis, which was unaffected by CsA but impaired by cardiac-specific Cnb1 deletion. In fact, our results in 
fibrosis using genetic approach are consistent with those obtained by overexpressing specifically in heart the Cn 
inhibitor, RCAN1 [44]. 
The effect of CsA treatment on different CH models has broadly been studied, obtaining controversial results 
about its CH inhibitory capacity [45]. Most studies that describe a CsA inhibitory effect on CH does not focus 
on its effect on fibrotic process induced in CH, and few studies that analyze it show opposing results. CsA-
mediated fibrosis attenuation [15] and exacerbation [46] have been described in AngII-non linked CH, while 
there is only one study in which it is described that CsA inhibits cardiac fibrosis mediated by an AngII-linked 
model, uninephrectomized and aldosterone-treated rats [17]. However, the result of systemic pharmacological 
inhibition of Cn on AngII-induced cardiac fibrosis has not been analyzed until the present work. The different 
doses of CsA and/ or different hypertrophic stimuli used in these studies could explain the discrepancies found.
Several studies have described myocardial fibrosis as a potential CsA side effect [46, 47], providing a possible 
explanation for the fibrotic phenotype in CsA-treated animals. However, this is unlikely to be the case in our 
experiments because CsA did not increase myocardial fibrosis in sham-implanted wild-type animals. In 
previous studies showing CsA-promoted fibrosis [46-48], the experiments used much higher CsA 
concentrations than those used here, suggesting that the pro-fibrotic effects might represent off-target effects on 
molecules other than Cn [23, 49]. Cardiac fibrosis induction can be in part a response to cell death [28], and 
high doses of CsA induces apoptosis [50]. In our genetic and pharmacological models, we found that the 
apoptotic and fibrotic responses follow a similar pattern in both experimental settings, and that CsA per se does 
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not induce apoptosis. CsA has also been found to increase Tgf-β1 levels in biopsies from immunosuppressed 
patients, animal models, and cells exposed to the drug in vitro [51-53]. A mechanism proposed for this effect is 
CsA-enhanced Tgf-β1 synthesis. However, in mice treated with CsA alone we detected no increase in cardiac 
Tgfβ1 mRNA (data not shown). Although we observed no CsA-mediated effect that explains the fibrosis results 
in CsA/AngII-treated mice, we cannot exclude the possibility that CsA posttranscriptionally or 
posttranslationally modifies a factor or factors involved in fibrosis [54, 55], producing an effect that is 
insufficient to induce fibrosis on its own but sufficient to maintain the induction of Tgfβ/fibrosis mediated by 
AngII.
An alternative hypothesis consistent with our results is that, in addition to its well-known phosphatase action, 
cardiac Cn is essential for the assembly of molecular signaling complexes in specific cardiomyocyte 
subdomains that could be implicated in AngII-induced fibrosis. Supporting this idea, anchoring of Cn to the 
sarcomere Z-disc is critical for the integration of cardiomyocyte stress signals [43]. Other possible explanation 
for divergent effects on AngII-induced cardiac fibrosis in two approaches to Cn inhibition may lie in the 
intricate intercellular crosstalk between fibroblasts and cardiomyocytes that has been described during AngII-
cardiac remodelling [56]. In contrast to cardiomyocyte-specific Cnb1 deletion, systemic inhibition of Cn 
mediated by CsA could have adverse profibrotic effect in other cell types of the heart or reveal differences in 
the Cn susceptibility to its activity inhibition by CsA depending on the cellular context in the similar way that 
differences in susceptibility of each tissue has been described [57]. Advances in the generation of Cre-
recombinase gene-targeted mice are enabling specific genetic manipulation of fibroblasts or differentiated 
myofibroblasts [58]. Future experiments taking avantage of these advances will allow us to explore the 
contribution of this cardiac cellular comparment to the observed fibrotic effects and to analyze possible 
differences in Cn susceptibilitly to drug-mediated inhibition depending on each cellular compartment.
In recent years, new factors have been identified and characterized that trigger and maintain the myocardial 
fibrotic response in different cardiac diseases [59]. An important role in pathological cardiac fibrosis was 
recently described for the lysyl oxidase (Lox) family of enzymes, which catalyze collagen assembly [34, 60-63]. 
Here we show that suppression of cardiac Cn impairs the transcriptional expression of Lox, which is involved in 
the progression of a pathological fibrotic response in the heart. However, CsA-mediated Cn inactivation does 
not affect the expression of Lox-family genes or the appearance of a fibrotic phenotype in the injured heart. The 
inhibition of AngII-induced cardiac fibrosis after cardiac-specific Cnb1 deletion likely involves the regulation 
of numerous genes; however, the marked inhibition of Tgfβ family members and Lox gene expression could 
probably account by itself for the decrease in the fibrotic phenotype. Tgfβ has been identified as an important 
upregulator of Lox enzymes in several cell types and tissues [62, 64-66]. Therefore the effect of Cn deletion on 
the cardiac expression of Tgfβ members could also underlie the Lox-mediated reduction of collagen fiber 
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maturation. Thus, the observed effects on fibrosis induction could reflect the direct fibroblast response to 
changes in Tgfβ or Lox expression. However, the effect of Cn deletion on the AngII-mediated apoptotic 
response in our experiments does not exclude the possibility that the inhibition of fibrosis in the absence of 
cardiomyocyte Cn is due in part to interference in AngII-induced cell death. This study reports a novel role of 
cardiomyocyte Cn, showing that Cn regulates pro-fibrotic gene expression and the progression of pathological 
cardiac fibrosis. Cardiac-specific Cn suppression is a potentially attractive therapeutic strategy. Future 
experiments will be required to clarify why cardiac fibrosis is inhibited by Cn genetic deletion but not by 
treatment with CsA, and future research is thus warranted into adeno-associated virus type 9-based clinical 
interventions for siRNA-mediated suppression of cardiomyocyte Cn expression. Our results highlight the 
importance of targeting Cn expression in the design of novel clinical interventions to prevent fibrosis in the 
injured heart, and also suggest that therapeutic strategies by targeting Lox should be explored.
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4. MATERIAL AND METHODS
4.1. Animals
All animal studies were conducted in accordance with EU Directive 2010/63/EU and Recommendation 
2007/526/EC regarding the protection of animals used for experimental and other scientific purposes, enforced 
in Spanish law under Real Decreto 1201/2005. C57BL/6J mice were obtained from Charles River laboratories.
To delete Cn specifically in cardiomyocytes, we crossed Cnb1∆/flox mice [25], in which one Cnb1 allele is 
deleted and the remaining allele is floxed, with Myh6CreERT2 transgenic mice [26] to obtain Cnb1Δ/flox; 
Myh6CreERT2 or Cnb1flox/flox; Myh6CreERT2 mice containing a floxed-version of the Cnb1 gene (Table in Fig. S1). 
Gross phenotype was assessed in animals of both genotypes maintained to the age of 6 months. In the absence 
of Cre-activation–induced Cnb1 deletion, mice with a single floxed Cnb1 allele (Cnb1Δ/flox) and mice with 2 
floxed Cnb1 alleles (Cnb1flox/flox) showed no significant differences in survival (Fig. S1C). As expected Cnb1 
mRNA levels in Cnb1Δ/flox mice were 50% of those of Cnb1flox/flox mice (Fig. S1A), however, similar CnB 
protein levels were detected in the different tissues analyzed, irrespective of the presence of one or two alleles 
Cnb1 gene, supporting haplo-sufficiency for the Cnb1 gene (Fig. S1D). After the Cre recombinase activation by 
4-hydroxy tamoxifen (Tx, Sigma-Aldrich, St.Louis, MO, USA, H6278) administration, both genotypes 
(Cnb1Δ/flox; Myh6CreERT2 and Cnb1flox/flox; Myh6CreERT2 mice) showed similar reductions in the levels of cardiac 
Cnb1 mRNA (Fig. S1A) and cardiac CnB and CnA protein (Fig. S1B). In Myh6CreERT2 mice, Cre recombinase 
activation in heart per se did not affect the expression of CnB and CnA proteins (Fig. S1E). Under baseline 
conditions, both genotypes showed no gross differences in phenotype or CnB and CnA protein expression, and 
both genotypes also displayed similar deletion levels of cardiac CnB after Cre activation; we therefore used 
mice of both genotypes in our experiments, hereafter referred to as Cnb1-floxMyh6 mice.
To achieve specific Cnb1 gene deletion in cardiomyocytes, Cnb1-floxMyh6 mice were injected intraperitoneally 
(ip.) with 40 mg/kg/day of Tx in corn oil [67] for 5 consecutive days between the ages of 8 and 12 weeks. To 
avoid interference from Cre activation or Tx treatment, experiments were conducted at least 2 weeks after the 
last Tx injection.
4.2. AngII treatment in vivo
Mice were anesthetized with 1.5% sevoflurane and fitted subcutaneously beneath the scapula with osmotic 
minipumps (model 2001 and 2004 Alzet; Durect Corporation, Cupernico, CA, USA) containing AngII (Sigma-
Aldrich, St.Louis, MO, USA, A9525, 60 µg/kg/h) or CsA (Novartis, Switzerland, 0.208 mg/kg/h). CsA-
containing minipumps were implanted 2 days before AngII minipumps to ensure pharmacological Cn inhibition 
before AngII administration. Control mice underwent the same surgical procedure but without minipump 
implantation (sham-implanted mice) [68]. 
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Mice were weighed and sacrificed after 1, 3, or 21 days of AngII treatment. Hearts were removed and the atria 
excised. The ventricles were weighed and dissected, with one part being processed for histology and another 
snap-frozen in liquid nitrogen for protein and RNA analysis. Liver, aorta, thymus and kidneys were also 
collected in liquid nitrogen. Tibias from left posterior limbs were isolated and measured with a digital caliper. 
4.3. Echocardiography 
Mice were lightly anesthetized with 1.5% isoflurane. Echocardiography was performed in the parasternal long-
axis view using the Vevo 2100 System (VisualSonics Inc., Toronto, Ontario, Canada) with a 30 MHz MS-400 
transducer in the 2-dimensional guided M-mode. Measurements were taken of diastolic interventricular and left 
ventricular posterior wall thicknesses, diastolic left ventricular diameter, and left ventricular ejection fraction.
4.4 Blood pressure 
Blood pressure and heart rate measurements were obtained using a noninvasive computerized tail-cuff system 
(BP-2000, Visitech Systems, NC, USA). Conscious mice from each group were placed on a warming plate and 
a cuff with a pneumatic pulse sensor was attached to the tail. Mice underwent training for 5 days, and on 
subsequent days the 10 first readings were discarded, and the mean of the following 10 measurements was 
calculated. 
4.5 Histology 
The central portion of the heart was fixed in 10% formalin solution (Sigma-Aldrich, 501128) and then 
embedded in paraffin. Transverse heart sections (5 µm) were obtained and used for analysis. To measure the 
cross-sectional area of left ventricular cardiomyocytes, heart sections were stained overnight at 4ºC with 100 
µg/ml FITC-conjugated Triticum vulgaris lectin (Sigma-Aldrich, L-4895). On each section, images were 
obtained from 4 fields with a Nikon Eclipse TE 2000-U fluorescence microscope (Nikon, Tokyo, Japan) fitted 
with a 10x objective. Cardiomyocyte area was calculated from these images using ImageJ [69].
To quantify cardiac fibrosis, serial transverse sections from each ventricle were stained with Picrosirius Red 
solution (Sigma Aldrich, P-6744-1GA/ 365548-5G) and the fibrotic area in the total section was quantified 
using ImageJ; fibrosis (red-stained area) was calculated as a percentage of the total section area. In each 
experiment, values were calculated relative to those from sham-implanted mice.
Apoptosis was detected by terminal dUTP nick-end labeling (TUNEL) assay using the ApopTag® Red In Situ 
Apoptosis Detection Kit (S7165, Millipore, Temecula, CA, USA) with some modifications. Briefly, apoptosis 
was detected by staining with PA(phosphatase alkaline)-conjugated anti-digoxigenin antibody. Heart sections 
were prepared for TUNEL assay according to the manufacturer’s instructions. Whole stained heart sections 
were scanned, and the extent of apoptosis was quantified using NDP.view2 software, Hamamatsu Photonics. 
The number of apoptotic cells (brown/black nuclei) in myocardium was quantified relative to the total 
transverse section area (mm2).
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4.6. Western blotting
Total protein from different tissues was extracted by pulverization with the MagnaLyser system (Roche) in lysis 
buffer (20 mM Tris-HCl pH 7.5, 1% Triton X-100, 50 mM NaF, 5 mM MgCl2, 500 mM NaCl, 10 mM EDTA, 
and proteases inhibitors: 100 µM benzamidin, 1µg/ml leupeptin, 1 µg/ml pepstatin, 1 µg/ml aprotinin, 1 µM 
ditiotreitol, 1 mM PMSF, and 3 mM EGTA). Homogenates were incubated on a rocking platform for 30 min at 
4ºC and centrifuged for 15 min at 16,000 x g at 4ºC, and soluble proteins were collected in the supernatants. 
Cardiac proteins were extracted in hypotonic buffer as previously described [70]. Briefly, pulverized heart was 
homogenized with a pestle and glass tube in a morter and pestle in hypotonic lysis buffer (10 mM Hepes pH 
7.4, 1.5 mM MgCl2, 10 mM KCl, 0.2% NP-40, 1 mM spermidine, 150 µM spermine, 10 mM MoO4Na2, and the 
protease inhibitors listed above). Homogenates were centrifuged for 15 min at 400 x g at 4ºC, and cytosolic 
proteins were collected in the supernatants. For both extractions, protein was quantified with the Bradford 
Protein Assay (Bio-Rad, Hercules, CA, USA).
Proteins from tissue lysates (30-50 µg) were separated by SDS-PAGE and transferred to nitrocellulose 
membranes. After blocking, the membranes were incubated with specific primary antibodies overnight at 4ºC 
(anti-Calcineurin B 1:2000, Upstate #cat 05-187; anti-Calcineurin PanA 1:1000, Chemicon #cat ab-1695; anti-
α-Tubulin 1:40000, Sigma-Aldrich #cat T-6074; anti-Gadph 1:1000, Abcam, Cambridge, United Kingdom, #cat 
ab8245; anti-α-Actinin 1:2000, Sigma-Aldrich #cat A-7811; anti-Rcan1 1:1000, Sigma-Aldrich #cat D6694; 
anti-Cox2 1:1000, Cayman, Ann Arbor, MI, USA, #cat 160126; and anti-Lox 1:2000, Abcam, Cambridge, 
United Kingdom, #cat ab31238). After washes and incubation with the appropriate specific HRP-conjugated 
secondary antibodies, immunoreactive bands were visualized using chemiluminescent substrate (ECL western 
blotting detection reagents, GE Healthcare, Chicago, IL, USA, RPN2106). Specific band intensities were 
quantified with Quantity One software (Bio-Rad). 
4.7. Quantitative RT-PCR
Total RNA was extracted from frozen and pulverized heart tissue using Trisure reagent (Bioline, Bio-38033) 
and the MagnaLyser system (Roche Life Science, Indianapolis, IN, USA). RNA was quantified and cDNA 
synthesized using 2 µg of total RNA and M-MLV reverse transcriptase (Promega, Madison, WI, USA, 
M170B). The resulting cDNA was analyzed by quantitative real-time PCR (qPCR) in an AB7900 sequence 
detection PCR system (Applied BiosystemFoster City, CA, USA) using SYBR Green PCR (Go Taq qPCR 
Master Mix, Promega, A600A) or TaqMan Universal PCR (Go Taq Probe PCR Master Mix, Promega, A610A). 
The following TaqMan probes were used: Rcan1.4 (Mm01213406_m1, Mm00627762_m1), Ptgs2 
(Mm00478374_m1), Il6 (Mm00446190_m1), and Hprt1 (Mm00446968_m1). The specific probes used for 
SYBR Green detection were as follows: Cnb1 (5’-TATTCGACACAGACGGCAAC-3’ and 5’-
CGAAAAGCAAACCTCAACTTC-3’), Col1a1 (5’-GCTCCTCTTAGGGGCCACT-3’ and 5’-
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CCACGTCTCACCATTGGGG-3’), Col3a1 (5’-CTGTAACATGGAAACTGGGGAAA-3’ and 5’-
CCATAGCTGAACTGAAAACCACC-3’), Tgf1 (5’-CGCCATCTATGAGAAAACC-3’ and 5’-
GTAACGCCAGGAATTGT-3’), Tgf2 (5’-CCACCTCCCCTCCGAAAA-3’, 5’-
AGACATCAAAGCGGACGATTCT-3’), Tgf3 (5’-GTCCTCAGTGGAGAAAAATGGAA -3’, 5’-
TTGGGCACCCGCAAGA-3’), Tgfi (5’-TCCTTGCCTGCGGAAGTG-3’, 5’-GGA 
GAGCATTGAGCAGTTCGA-3’), Lox (5´-TGCGCTGCGGAAGAAAA-3´, 5´-
TCTGACATCCGCCCTATATGC-3´), Loxl1 (5´-CAGTGGATCGACATAACTGATGTG-3´, 5´-
GGGTTCACGTGCACCTTGA-3´), Loxl2 (5´-CCTCAAGGTTCCGGAAAGC-3´, 5´-
ACCTCTCAGGCGCACCAA-3´), Loxl3 (5´-TGTGCCTAGTCGAAGTGCC-3´, 5´-
GTGTAGCAGCAGTAGTCCCC-3´), Loxl4 (5´-TTGCTCTCAAGGACACCTGGTA-3´, 5´-
GCAGCGAACTCCACTCATCA-3´), and Gadph (5’-TGCACCACCAACTGCTTAGC-3’ and 5’-
GGCATGGACTGTGGTCATGAG-3’). Target gene expression was estimated with the comparative 2-ΔΔCT 
method, using Hprt1 or Gadph transcripts for normalization. Fold changes in normalized target gene expression 
were expressed relative to the mean values obtained from sham-operated mice, except for Cnb1 mRNA 
expression, which is expressed as raw data.
4.8. Statistical analysis
All data are presented as means ± SEM (standard error of the mean). Statistical differences were analyzed with 
Graph-Pad Prism Version 7.03 (GraphPad, Inc., La Jolla, CA, USA). Data from different experimental groups 
were compared by one-way ANOVA followed by Tukey test, and the adjusted P values for multiples 
comparisons are indicated. Where indicated, comparisons between 2 groups were also made by unpaired, two-
tailed Student t test. Differences were considered statistically significant at P≤0.05. The number of samples and 
independent experiments in each analysis are indicated in the corresponding figure legend. 
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FIGURE LEGENDS
Fig. 1. Cn inhibition by CsA attenuates cardiac hypertrophy induced by pressor doses of AngII. Wild type 
mice were minipump-infused with AngII (60 µg/kg/h) in the presence (CsA/AngII) or absence of CsA (0.208 
mg/kg/h) for 21 days. Control mice underwent surgery without minipump implantation (sham). (A) Ratios of 
ventricular weight to body weight (VW/BW) and ventricular weight to tibial length (VW/TL). Symbols 
represent data from individual mice; horizontal lines show means ± SEM (n=7-17 mice/group, 3 independent 
experiments). (B) Analysis of cardiomyocyte cross-sectional area on cardiac histological sections stained with 
FITC-T. vulgaris lectin. Images show representative microscopy fields. Scale bar, 50 µm. The histogram shows 
individual data and means ± SEM (n=7-19 mice/group, 4 independent experiments). Data in A and B were 
analyzed by one-way ANOVA with a post hoc Tukey comparison test, the adjusted P values are shown.
Fig. 2. AngII induces the early appearance of a Cn-dependent cardiac hypertrophic phenotype. (A) qPCR 
analysis of Rcan1.4 and Ptgs-2 gene expression in the hearts of mice treated with AngII (60 µg/kg/h) as 
indicated. Results are expressed as fold-increase relative to control animals (sham). Data are means ± SEM 
(n=2-3 mice/group). (B) Western blot analysis of Rcan1.4 protein expression in the hearts of mice treated with 
AngII (60 µg/kg/h) for 1 day in the presence or absence of CsA (0.208 mg/kg/h). Expression of -Tubulin (α-
Tub) was determined as a loading control. The presented blot is representative of 3 experiments. (C) Western 
blot analysis of Rcan1.4 and Cox-2 protein expression in heart protein lysates from wild-type mice infused for 1 
or 2 days with AngII (60 µg/kg/h) in the presence or absence of CsA (0.832 mg/kg/h). Levels of α-Actinin (α-
Act) were determined as a loading control (D-F) Analysis of cardiac hypertrophy in mice treated as indicated 
for 1 or 3 days. (D) Ratios of ventricular weight to body weight (VW/BW) and ventricular weight to tibia length 
(VW/TL). (E) Cardiomyocyte cross-sectional area. (F) Interventricular septum wall thickness. Histograms show 
individual data and means ± SEM (n=12-14 mice/group, 3 independent experiments in D and n=9-12 
mice/group, 2 independent experiments in E and F). All data were analyzed by one-way ANOVA with a post 
hoc Tukey comparison test, the adjusted P values are shown. Parameters in D were compared by unpaired, two-
tailed Student t test; *P.
Fig. 3. Cardiac Cnb1 deletion reduces AngII-induced Rcan1.4 and Ptgs2 expression in the heart. (A) 
Western blot analysis of calcineurin subunit A (CnA) and subunit B (CnB) expression in the hearts of Cnb1-
floxMyh6 mice after treatment with vehicle (Veh) or 4-hydroxy tamoxifen (Tx). Expression of α-Tubulin (α-Tub) 
was determined as a loading control. (B) Western blot analysis of CnB expression in protein lysates from thymus, 
aorta, kidney, and liver Cnb1-floxMyh6 mice treated with vehicle (Veh) or 4-hydroxy tamoxifen (Tx). α-Tubulin 
(α-Tub) was analyzed as a loading control. (C) qPCR analysis of Rcan1.4 and Ptgs2 mRNA expression in Cnb1-
floxMyh6 mice treated with 4-hydroxy tamoxifen (Tx) or vehicle (Veh) and subsequently infused with AngII for 1 
day. Data are means ± SEM (n=2-7 mice/group), and were analyzed by one-way ANOVA with a post-hoc Tukey 
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comparison test, the adjusted P values are shown (D) Western blot analysis of Rcan1.4 protein expression in 
Cnb1-floxMyh6 mice treated with AngII for 1 day. α-Tubulin (α-Tub) was analyzed as loading control. 
Fig. 4. Specific deletion of Cn in the adult heart impairs AngII-mediated cardiac hypertrophy. (A) Ratios 
of ventricular weight to body weight (VW/BW) and ventricular weight to tibia length (VW/TL) in Cnb1-floxMyh6 
mice treated with vehicle or Tx and subsequently infused with AngII or CsA plus AngII (CsA/AngII) for 21 days. 
(B) Cardiomyocyte cross-sectional area in mice treated as in A. Histograms in A and B show individual data and 
means ± SEM (n=10-20 mice/group, ≥3 independent experiments). Images show representative cardiac cross-
sectional microscopy fields quantified in the histogram. Scale bar, 50 µm. Data were analyzed by one-way 
ANOVA with a post hoc Tukey comparison test. 
Fig. 5. Expression of cardiac Cn is required for AngII-induced fibrosis in the heart. (A-B) Picrosirius Red 
staining of collagen on histological sections of hearts isolated from wild type mice infused for 21 days (A) or 1 
and 3 days (B) with AngII (60 µg/kg/h) in the presence or absence of CsA (0.208 mg/kg/h). Histograms show 
individual data and means ± SEM (n=8-15 mice/group, ≥2 independent experiments). Images show 
representative staining in experiments quantified in the histogram in A. Scale bar, 1 mm. (C) qPCR analysis of 
Col3a1 RNA in the hearts of wild-type mice treated as above for 1 and 3 days. Data are means ± SEM (n=7-13 
mice/group, 2 independent experiments). (D) Picrosirius Red staining of collagen on histological sections of 
hearts isolated from Cnb1-floxMyh6 mice treated with vehicle (Veh) or 4-hydroxy tamoxifen (Tx) and 
subsequently infused with AngII for 21 days. When indicated, AngII-infused animals were co-treated with CsA. 
Images show representative staining in experiments quantified in the histogram. Scale bar, 1 mm. The 
histogram shows individual data and means ± SEM (n=11-14 mice/group, 3 independent experiments). All data 
were analyzed by one-way ANOVA with a post hoc Tukey comparison test. Parameters in B were compared by 
unpaired, two-tailed Student t test; *P.
Fig. 6. Cardiac Cnb1 deletion attenuates CH and fibrosis at the onset of the disease. Cnb1-floxMyh6 mice were 
treated with vehicle (Veh) or 4-hydroxy tamoxifen (Tx) and subsequently infused with AngII for 3 days. (A) 
Ventricular weight to body weight (VW/BW) ratio. (B) Ventricular weight to tibia length (VW/TL) ratio. (C) 
Interventricular septum wall thickness. (D) Cardiac fibrosis, measured as Picrosirius Red collagen staining on 
histological sections. Data are means ± SEM (n=7-15 mice/group, 2 or 3 independent experiments). Data were 
analyzed by one-way ANOVA with a post hoc Tukey comparison test, the adjusted P values are shown. For 
VW/TL ratios, comparisons between 2 groups were made by unpaired, two-tailed Student t test; *P.
Fig. 7. Cardiac Cnb1 deletion reduces AngII-induced apoptosis in the heart. TUNEL assays on histological 
sections of hearts isolated from (A) wild type mice infused for 3 days with AngII (60 µg/kg/h) in the presence 
or absence of CsA (0.208 mg/kg/h) or (B) from Cnb1-floxMyh6 mice treated with vehicle (Veh) or 4-hydroxy 
tamoxifen (Tx) and subsequently infused with AngII for 3 days. Histograms show individual data and means ± 
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SEM (n=4 mice/group). Images show representative staining in each group. Scale bar, 50 µm. All data were 
analyzed by one-way ANOVA with a post hoc Tukey comparison test. Nuclei from apoptotic cells are stained 
in brown/black.
Fig. 8. Cardiac Cn expression is essential for the expression of specific pro-fibrotic genes. (A) qPCR 
analysis of pro-fibrotic genes in the heart of wild-type mice after infusion with AngII for 1 and 3 days. Data are 
means ± SEM, n=4-6 mice/time point and were analysed by one-way ANOVA with a post hoc Tukey 
comparison test; the adjusted P values are shown; *P value was acquired by unpaired, two-tailed Student t test. 
(B) qPCR analysis of pro-fibrotic genes in the hearts of CsA-treated wild-type mice (left) or Tx-treated Cnb1-
floxMyh6 mice (right) after AngII infusion for the optimal period for each gene, obtained from results in A (1 day 
after AngII infusion except for Tgfβ3, which was analyzed 3 days after AngII infusion). Data are means ± SEM 
(n=4-6 mice/group for Il6 and Tgfβ3; n=7-14 mice/group for Tgfβ1, Tgfβ2, and Tgfβi). (C) qPCR analysis of 
collagen genes in the hearts of CsA-treated wild-type mice (left) or Tx-treated Cnb1-floxMyh6 mice (right) after 
AngII infusion for 3 days. Data are means ± SEM (n=5-8 mice/group). (D) qPCR analysis of Lox in the hearts 
of CsA-treated wild-type mice (left) or Tx-treated Cnb1-floxMyh6 mice (right) after AngII infusion for 1 day. 
Data are means ± SEM (n=8-14 mice/group). Data in B-D were obtained from 3 independent experiments, and 
were analyzed by one-way ANOVA with a post Tukey comparison test, *P value was acquired by unpaired, 
two-tailed Student t test (E) Western blot analysis of Lox protein expression in cardiac protein lysates isolated 
from the experimental mouse models described above after AngII infusion for 3 days. Levels of α-Tubulin (α-
Tub) were determined as a loading control; n=3-5 mice/group. Arrows indicate the specific Lox protein band.
Fig. 9. AngII-induced expression of Loxl4 is selectively affected by cardiac-specific Cn deletion. qPCR 
analysis of Loxl genes (Loxl1, Loxl2, Loxl3 and Loxl4) in the hearts of CsA-treated wild-type mice (left) and Tx-
treated Cnb1-floxMyh6 mice (right) after AngII infusion for 1 day. Data are means ± SEM (n=6-14 mice/group), 
and were analyzed by one-way ANOVA with a post hoc Tukey comparison test, the adjusted P values are shown 
For Loxl3 expression in wild-type mice, comparisons between 2 groups were made by unpaired, two-tailed 
Student t test; *P.
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Table 1. Effect of a pharmacological CsA concentration (0.208 mg/kg/h) on echocardiographic parameters 
and systolic blood pressure determined in wild-type control (sham-implanted) mice or mice infused with 
AngII (60 µg/kg/h) for 21 days.
IVS d, diastolic interventricular septum thickness; LVPW d, diastolic left ventricular posterior wall thickness; 
LVID d, diastolic left ventricle internal diameter; EF, ejection fraction; SBP, systolic blood pressure; bpm, beats 
per minute.
Data are means ± SEM (n=9-15 mice/group, from 3 independent experiments), and were analyzed by one-way 
ANOVA with a post hoc Tukey comparison test; and the adjusted P values are shown: #P vs sham group; †P vs 
AngII group
sham AngII CsA CsA/AngII
Heart rate
(bpm)
488 ± 15 515 ± 13 528 ± 21 499 ± 19
IVS, d
(mm)
0.76 ± 0.02 0.94 ± 0.03
(#P<0.0001)




0.75 ± 0.02 0.85± 0.03
(#P=0.0277)
0.70 ± 0.01 0.79 ± 0.03
LVID, d
(mm)
3.88 ± 0.06 3.75 ± 0.09 3.86 ± 0.08 3.79 ± 0.07
EF
(%)
52.5 ± 1.6 50.7 ± 2.3 49.9 ± 2.2 45.8 ± 2.3
Systolic BP
(mmHg)
109.7 ± 3.0 145.1 ± 6.7
(#P<0.0001)
113.4 ± 1.9 143.5 ± 4.1
(#P<0.0001)
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Table 2. Echocardiographic parameters in Cnb1-floxMyh6 mice treated with vehicle or 4-hydroxy tamoxifen 
(Tx) and subsequently infused with AngII for 21 days.
IVS d, diastolic interventricular septum thickness; LVPW d, diastolic left ventricular posterior wall thickness; 
LVID d, diastolic left ventricle internal diameter; EF, ejection fraction; bpm, beats per minute.
Data are means ± SEM (n=8-10 mice/group, 2 independent experiments), and were analyzed by one-way ANOVA 
with a post hoc Tukey comparison test; and the adjusted P values are shown: #P vs sham group; †P vs AngII group.
sham AngII Tx/sham Tx/AngII
Heart rate
(bpm)
504 ± 24 574 ± 14 542 ± 26 511 ± 17
IVS, d
(mm)
0.73 ± 0.02 0.94 ± 0.04
(#P<0.0001)
0.74 ± 0.02 0.84 ± 0.03
LVPW, d
(mm)
0.71 ± 0.02 0.96 ± 0.03
(#P<0.0001)




3.72 ± 0.10 3.35 ± 0.16 3.54 ± 0.11 3.38 ± 0.09
EF
(%)
48.7 ± 2.0 56.3 ± 2.2 61.8± 2.4
(#P=0.0013)
52.3 ± 2.7
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